CURx Pharmaceuticals announced it has entered into a global license agreement with Gilead Sciences Inc. for development of Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. FTI is ready for Phase 3 clinical trials, having successfully completed a Phase 2 trial in CF patients.
“This is a great acquisition for CURx Pharmaceuticals which enables us to expand our portfolio and also to provide another inhaled therapeutic to the cystic fibrosis community,” said Dinu Sen, CEO and founder of CURx. “Clinical trials in CF patients with Pseudomonas aeruginosa infection have demonstrated FTI’s safety and efficacy. Future trials may pave the way for its use against a range of bacterial infections in CF- there is an unmet need for antibiotics with such characteristics.”
“Lung infections continue to be a serious problem for individuals with cystic fibrosis,” commented Dr. Drucy Borowitz, director of the Cystic Fibrosis Center of Western New York. “If further studies confirm that (FTI) is safe and efficacious it will be a significant addition to improving the health of people with CF.”
Dr. Patrick Flume, director of the Cystic Fibrosis Center at Medical University of South Carolina added “Currently we have two drugs approved in the U.S. for use in CF patients, but there remains a need for more options. The CF community welcomes the development of new treatment options such as FTI.”
Date: February 19, 2014
Filed Under: Drug Discovery